In this episode, we bring you pearls and perspectives from Hawaiian Eye 2020.
- Ashley Brissette, MD, MSc, FRCSC, considers the importance of testing for inflammation and dry eye before performing cataract surgery :17
- Ryan Bleeks, of Sun Ophthalmics, shares an update on Cequa - cyclosporine ophthalmic solution 0.09% - for the treatment of dry eye disease 2:45
- Jay S. Pepose, MD, PhD, discusses treatment options for varicella zoster 4:04
- Jennifer M. Loh, MD, discusses the impact that sharing a meibomian gland image can have in patient treatment 6:04
- Brandon Ayres, MD, examines the use of the FDA-approved epi-off corneal cross-linking procedure 7:16
- John P. Berdahl, MD, discusses the benefits of compounded medications that are unique to ophthalmology 10:18
- Femida Kherani, MD, shares pearls for incorporating dermal fillers and neuromodulators 12:13
- Craig N. Piso, PhD, shares pearls for improving ophthalmic technician performance 13:01
- Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses results of the MOST phase 4 trial 14:30
- Richard S. Davidson, MD, discusses surgical correction for keratoconus 15:43
- Steven D. Vold, MD, discusses the use of Vyzulta -latanoprostene bunod ophthalmic solution 0.024% by Bausch + Lomb 17:00
- Thanks for listening 18:45
Disclosures: Ayres reports being a paid consultant to Glaukos. Bleeks is an employee of Sun Ophthalmics. Brissette reports being a paid consultant to Alcon and Zeiss. Loh reports being a paid consultant to Sight Sciences. Mitro is president and COO of Aerie Pharmaceuticals. Vold reports being a paid consultant to Bausch + Lomb. Davidson, Kherani, Pepose and Piso report no relevant financial disclosures.
